

# CITATION REPORT

List of articles citing

## Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?

DOI: 10.3389/fimmu.2020.01969  
Frontiers in Immunology, 2020, 11, 1969.

**Source:** <https://exaly.com/paper-pdf/76226643/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2. <i>ACS Pharmacology and Translational Science</i> , <b>2020</b> , 3, 1361-1370	5.9	9
4	Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	8
3	HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 621054	5.6	4
2	Effects of Hydroxychloroquine and Azithromycin on iPSC-derived Cardiomyocytes: Considerations for the Treatment of COVID-19 Patients.		1
1	Structure of acute chemical poisoning during COVID-19 pandemic (according to a multidiscipline hospital). <i>Toxicological Review</i> , <b>2022</b> , 30, 4-11	0.2	